Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.74 |
| ▸ | CDK9 | P50750 | 3/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.73 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.64 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.61 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867751 | 0.88 | CDK2 (0.69) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL5867369 | 0.84 | CDK2 (0.68) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL6385624 | 0.84 | CDK2 (1.00) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL5867666 | 0.82 | CDK2 (0.72) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL5868090 | 0.82 | CDK2 (0.72) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL25649664 | 0.82 | CDK2 (0.78) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL25225939 | 0.81 | CDK2 (0.91) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL6386188 | 0.80 | CDK2 (0.81) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL5867462 | 0.80 | CDK2 (0.67) | CDK2CDK5CDK9CCNE1CDK5R1 | |
| SCHEMBL5867817 | 0.80 | CDK2 (0.66) | CDK2CDK5CDK9CCNE1CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209297-A1 | Pyrazole derivatives | PFIZER INC | 2005-09-22 | — | — | US | disclosed |
| EP-1313710-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020103185-A1 | Pyrazole derivatives | PFIZER PRODUCTS INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002018346-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209297-A1 | Pyrazole derivatives | CDK1, CDK3, CDK5 | CDK2 7/4885CDK5 3/4885CDK9 58/4885 |
| US-20020103185-A1 | Pyrazole derivatives | CDK1, CDK5, CDK3 | CDK2 5/4885CDK5 2/4885CDK9 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.